CJC-1295 (with DAC) vs Ipamorelin
Two growth hormone secretagogues that work on opposite halves of the same axis.
The short answer: CJC-1295 amplifies the size of GH pulses; ipamorelin triggers them.
CJC-1295 (with DAC)
Ipamorelin
Side by side
| Property | CJC-1295 (with DAC) | Ipamorelin |
|---|---|---|
| Research category | Growth Research | Growth Research |
| Presentation | 5mg vial | 10mg vial |
| Dosage options | 5mg | 10mg |
| Approved medicine using it | None — investigational | None — investigational |
| Availability | Low stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €99.00 | €42.90 |
How they differ
Growth hormone release is governed by two opposing signals: GHRH, which stimulates, and somatostatin, which inhibits. These two compounds enter that system at different points.
CJC-1295 is a GHRH analog. It acts on the GHRH receptor and is associated with increased amplitude of existing pulses. Ipamorelin is a ghrelin mimetic acting on the GHS-R receptor, associated with initiating pulses and with a selectivity that distinguishes it from earlier secretagogues in the class.
Because one raises pulse height and the other pulse frequency, they are complementary rather than competing — the reason they appear together in so much of the literature.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.